Last reviewed · How we verify

NCT06266403

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

Recruiting now NA Last updated 13 January 2025
What this trial tests

NA trial testing Structured Communicative Interaction in Amyotrophic Lateral Sclerosis in 300 participants. Currently enrolling.

Timeline
5 November 2024
Primary endpoint
28 February 2029
28 February 2029

Quick facts

Lead sponsorPenn State University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment300
Start date5 November 2024
Primary completion28 February 2029
Estimated completion28 February 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Penn State University

Who can join

Adults 18 to 90, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS? Participants will read words and sentences while they are in a solo setting and interactive setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Structured Communicative Interaction

Trials testing the same drug.

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

Other Penn State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06266403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing